GM1 Ganglioside-based Therapies
Neurological Disorders
Commercial / DevelopmentActive
Key Facts
Indication
Neurological Disorders
Phase
Commercial / Development
Status
Active
Company
About TRB Chemedica International
TRB Chemedica International is a well-established, privately-held Swiss pharma and biotech company with over 40 years of history. It has a global commercial footprint, supported by over 900 employees, 20+ international subsidiaries, and manufacturing sites in Switzerland, Argentina, and Brazil. The company's strategy centers on developing and marketing specialized products in ophthalmology, rheumatology, and neurology, built on deep expertise in key therapeutic compounds and a partnership-driven business model that includes in-licensing and out-licensing.
View full company profileTherapeutic Areas
Other Neurological Disorders Drugs
| Drug | Company | Phase |
|---|---|---|
| Biomarker Development Program | NeuroVision Imaging | Research |
| GlyT2 Inhibitor Program | Micar Innovation | Discovery |
| Biomarker Discovery & Validation Services | NeuroDex | Service |
| Clinical Trial Biomarker Support | NeuroDex | Service |
| CNS-Targeting Capsids | rAAVen Therapeutics | Pre-clinical |
| IVL-002 | InVirtuoLabs | Discovery |
| IVL-003 | InVirtuoLabs | Discovery |
| Neurology Diagnostics Program | Aptus Biosciences | Discovery |
| Undisclosed Neurology Programs | BridGene Biosciences | Discovery |
| iPSC Platform Programs | Evotec | Preclinical Research |
| ExacTcell Platform | Tevogen Bio | Discovery/Preclinical |